Evidence map›Paper›PMID 35349755›Full record

Observational studyImmunity, inflammation and disease2022

Blood myxovirus resistance protein-1 measurement in the diagnostic work-up of suspected COVID-19 infection in the emergency department.

Kirby Tong-Minh, Samantha van Hooijdonk, Marjan A Versnel, Cornelia G van Helden-Meeuwsen, Petrus Martin van Hagen, Eric C M van Gorp, Henrik Endeman, Yuri van der Does, Virgil A S H Dalm, Willem A Dik

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Immunity, inflammation and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Assessing Biomarkers in Viral Infection.Advances in experimental medicine and biology · 2023
    Review
  8. Article
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kirby Tong-MinhDepartment of Emergency Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-8373-0011
Samantha van HooijdonkDepartment of Emergency Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Marjan A VersnelDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Cornelia G van Helden-MeeuwsenDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Petrus Martin van HagenDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Eric C M van GorpDepartment of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands.
Henrik EndemanDepartment of Intensive Care, Erasmus University Medical Center, Rotterdam, The Netherlands.
Yuri van der DoesDepartment of Emergency Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Virgil A S H DalmDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Willem A DikLaboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Erasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMyxovirus resistance protein 1 (MxA) is a biomarker that is elevated in patients with viral infections. The goal of this study was to evaluate the diagnostic value of MxA in diagnosing COVID-19 infections in the emergency department (ED) patients.

methodsThis was a single-center prospective observational cohort study including patients with a suspected COVID-19 infection. The primary outcome of this study was a confirmed COVID-19 infection by RT-PCR test. MxA was assessed using an enzyme immunoassay on whole blood and receiver operating chart and area under the curve (AUC) analysis was conducted. Sensitivity, specificity, negative predictive value, and positive predictive value of MxA on diagnosing COVID-19 at the optimal cut-off of MxA was determined.

resultsIn 2021, 100 patients were included. Of these patients, 77 patients had COVID-19 infection and 23 were non-COVID-19. Median MxA level was significantly higher (p < .001) in COVID-19 patients compared to non-COVID-19 patients, respectively 1933 and 0.1 ng/ml. The AUC of MxA on a confirmed COVID-19 infection was 0.941 (95% CI: 0.867-1.000). The optimal cut-off point of MxA was 252 ng/ml. At this cut-off point, the sensitivity of MxA on a confirmed COVID-19 infection was 94% (95% CI: 85%-98%) and the specificity was 91% (95% CI: 72%-99%).

conclusionMxA accurately distinguishes COVID-19 infections from bacterial infections and noninfectious diagnoses in the ED in patients with a suspected COVID-19 infection. If the results can be validated, MxA could improve the diagnostic workup and patient flow in the ED.

Indexed as

COVID-19OrthomyxoviridaeEmergency Service, HospitalHumansMyxovirus Resistance ProteinsProspective StudiesMyxovirus Resistance ProteinsbiomarkerCOVID-19emergency departmentMxA

Identifiers

PMID35349755
PMCPMC8962640
OpenAlexW4220730140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.